A detailed history of New York State Common Retirement Fund transactions in Ardelyx, Inc. stock. As of the latest transaction made, New York State Common Retirement Fund holds 248,544 shares of ARDX stock, worth $1.19 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
248,544
Previous 284,044 12.5%
Holding current value
$1.19 Million
Previous $2.11 Million 18.67%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 28, 2024

SELL
$5.28 - $7.57 $187,440 - $268,735
-35,500 Reduced 12.5%
248,544 $1.71 Million
Q2 2024

Jul 31, 2024

BUY
$5.89 - $9.31 $1,955 - $3,090
332 Added 0.12%
284,044 $2.11 Million
Q1 2024

May 07, 2024

BUY
$6.05 - $9.74 $387 - $623
64 Added 0.02%
283,712 $2.07 Million
Q4 2023

Feb 01, 2024

BUY
$3.29 - $6.64 $25,349 - $51,161
7,705 Added 2.79%
283,648 $1.76 Million
Q3 2023

Nov 07, 2023

BUY
$3.3 - $4.83 $7,401 - $10,833
2,243 Added 0.82%
275,943 $1.13 Million
Q2 2023

Aug 07, 2023

BUY
$3.23 - $4.95 $269,705 - $413,325
83,500 Added 43.9%
273,700 $928,000
Q1 2023

May 02, 2023

BUY
$2.68 - $4.79 $509,736 - $911,058
190,200 New
190,200 $911,000
Q2 2022

Aug 04, 2022

SELL
$0.51 - $1.17 $30,447 - $69,849
-59,700 Reduced 98.59%
856 $1,000
Q3 2021

Nov 02, 2021

SELL
$1.27 - $8.17 $15,788 - $101,569
-12,432 Reduced 17.03%
60,556 $80,000
Q2 2021

Aug 02, 2021

BUY
$6.55 - $8.98 $108,651 - $148,960
16,588 Added 29.41%
72,988 $553,000
Q2 2020

Aug 07, 2020

BUY
$5.37 - $8.11 $126,732 - $191,396
23,600 Added 71.95%
56,400 $390,000
Q2 2017

Aug 11, 2017

BUY
N/A
32,800
32,800 $167,000

Others Institutions Holding ARDX

About ARDELYX, INC.


  • Ticker ARDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 154,636,000
  • Market Cap $742M
  • Description
  • Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel synd...
More about ARDX
Track This Portfolio

Track New York State Common Retirement Fund Portfolio

Follow New York State Common Retirement Fund and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of New York State Common Retirement Fund, based on Form 13F filings with the SEC.

News

Stay updated on New York State Common Retirement Fund with notifications on news.